Alpha 2.0
Login Register
» Authors » Alan Solinger

Alan Solinger

Explore the profile of Alan Solinger including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 475
Followers 0
Related Specialties
Rheumatology
Allergy & Immunology
Top 10 Co-Authors
Paul Scholl
Stella Aslanyan
Sudha Visvanathan
Roy Fleischmann
Cecilia Garlanda
Bojan Lalovic
H Muehl
James G Krueger
Mikkel Ostergaard
Mihai Netea
Published In
J Rheumatol
Ann Rheum Dis
J Allergy Clin Immunol
Nat Immunol
Affiliations
Soon will be listed here.
Recent Articles
1.
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
Baeten D, Ostergaard M, Cheng-Chung Wei J, Sieper J, Jarvinen P, Tam L, et al.
Ann Rheum Dis . 2018 Jun; 77(9):1295-1302. PMID: 29945918
Objectives: To evaluate the efficacy and safety of risankizumab, a humanised monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), in patients with active ankylosing spondylitis (AS). Methods: A total...
2.
Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial
Krueger J, Ferris L, Menter A, Wagner F, White A, Visvanathan S, et al.
J Allergy Clin Immunol . 2015 Mar; 136(1):116-124.e7. PMID: 25769911
Background: IL-23 is associated with plaque psoriasis susceptibility and pathogenesis. BI 655066 is a fully human IgG1 mAb specific for the IL-23 p19 subunit. Objective: This first-in-human proof-of-concept study evaluated...
3.
Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study
Gul A, Tugal-Tutkun I, Dinarello C, Reznikov L, Esen B, Mirza A, et al.
Ann Rheum Dis . 2011 Nov; 71(4):563-6. PMID: 22084392
Objective: Uveitis and retinal vasculitis are sight-threatening manifestations of Behçet's disease with limited treatment options. This pilot study aimed to evaluate the safety, pharmacokinetics and clinical activity of XOMA 052...
4.
IL-1 family nomenclature
Dinarello C, Arend W, Sims J, Smith D, Blumberg H, ONeill L, et al.
Nat Immunol . 2010 Oct; 11(11):973. PMID: 20959797
No abstract available.
5.
Etanercept in adult patients with early onset ankylosing spondylitis
Inman R, Clegg D, Davis J, Whitmore J, Solinger A
J Rheumatol . 2006 Aug; 33(8):1634-6. PMID: 16881118
Objective: To determine whether twice-weekly subcutaneous etanercept improves the signs and symptoms of adult patients with early onset ankylosing spondylitis (AS). Methods: A retrospective analysis was performed on a subgroup...
6.
A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis
Furst D, Fleischmann R, Kopp E, Schiff M, Edwards 3rd C, Solinger A, et al.
J Rheumatol . 2005 Dec; 32(12):2303-10. PMID: 16331754
Objective: In a phase 2 study, to assess the efficacy and safety of pegsunercept, a soluble tumor necrosis factor receptor type I, for the treatment of rheumatoid arthritis (RA). Methods:...
7.
Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis
Tesser J, Fleischmann R, Dore R, Bennett R, Solinger A, Joh T, et al.
J Rheumatol . 2004 Apr; 31(4):649-54. PMID: 15088288
Objective: To examine the safety of anakinra when added to a background of standard rheumatoid arthritis (RA) medications in patients with RA with active disease. Methods: This analysis further evaluates...